Results published today reveal QBiotics ’ STELFONTA®(tigilanol tiglate) removes 75% of tumours
Brisbane Australia, WEDNESDAY, JUNE 17, 2020 – The Journal ofVeterinary Internal Medicine has today published results from a pivotal caninefield study of STELFONTA® (tigilanol tiglate), the lead anticancerpharmaceutical from Australian life sciences company, QBiotics Group Limited(QBiotics).
The study of 123 client-owned dogs demonstrated that in those with Mast CellTumours (MCTs), a single intratumoural injection of STELFONTA® removed 75% ofMCTs at day 28, significantly higher compared to untreated controls (p<0.001).Further, the trial showed no recurrence in 93% of STELFONTA®-treated dogs atday 84. Importantly, the treatment was well tolerated, and animals had a goodquality of life during and after treatment.1
STELFONTA® is a first-in-class pharmaceutical treatment for all grades of MCTnow available in Europe with anticipated launches in the USA and Australia,pending approvals.
Dr Chad Johannes, a leading USA veterinary oncologist said, “The studydetermined STELFONTA® is an efficacious and well-tolerated new option for thelocal treatment of canine MCT.
“STELFONTA® is administered by injection directly into the tumour. Generally,dogs undergoing treatment do not require sedation or anaesthesia, whichcarries potential increased risk for older dogs and brachycephalic breeds,”said Dr Johannes.
Cancer is the leading cause of death in dogs,2 and MCTs are the second mostfrequent canine cancer diagnosed.3 STELFONTA® represents an excitingadditional treatment option for MCT where surgical removal of the tumour massis currently the standard of care.
The launch of STELFONTA® marks the first commercialisation of QBiotics’ leadanticancer compound tigilanol tiglate and creates a repeatable revenue streamfor the company.
QBiotics’ CEO and Managing Director, Dr Victoria Gordon said “The inclusion ofour pivotal safety and efficacy clinical study in such a reputable publicationas the Journal of Veterinary Internal Medicine is a significant accolade forQBiotics and reaffirms the validity of the study’s results.
“Having recently launched STELFONTA® in Europe, our marketing partner theglobal veterinary pharma company, Virbac, will work to distribute the productlocally amidst country-specific COVID-19 requirements. We also advise thatSTELFONTA® may be launched in the USA and Australia, pending local approvals.
“Here at QBiotics we develop our products simultaneously for the human andveterinary markets. The sound results from the tigilanol tiglate pivotalcanine field study informs our human clinical program, while revenue fromsales of STELFONTA® financially supports human product development,” said DrGordon
Previous China International Pet Show (CIPS) Releasing Her Online Trade ShowPlatform
Next Thinking about inviting a new bestie into the family